Expression of malaria polypeptides
CA 2095540 A1 · Owner: Gibson, Helen L. · Inventors: Barr, Philip J.; Gibson, Helen L.; Bathurst, Ian C.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to recombinant expression of malaria polypeptides. Nucleic acid constructs having a domain encoding a malaria polypeptide, preferably SERA or an epitope-containing fragment thereof, downstream from a domain encoding a ubiquitin polypeptide are presented. Additionally constructs with a, third domain encoding an immunomodulator polypeptide preferably, human .gamma.-interferon, and positioned between the first and second domains encoding, respectively, ubiquitin and a malaria polypeptide are also included. The malaria polypeptides of the present invention have utility as vaccine candidates and in immunodiagnostic applications.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 7, 1990. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 7, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 7, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.